Forecast

There is no analyst data available for this company.

News Go to news feed

Merck KGaA gains after HSBC upgrade, breaks technical trendlines

HSBC upgraded Merck KGaA from “hold” to “buy,” sending the stock up about 1.9% on Tuesday to €141.60. Analyst Rajesh Kumar cites valuation and notes that Merck had not fully participated in the recent sector rally. While growth in the life-science segment is likely to lag behind the first half of 2026 in the coming quarters, the fundamental growth drivers remain intact. From a chart perspective, the stock has broken above the 21- and 50-day moving averages, bringing the early July and August highs at just under €149 back into focus. » More on de.investing.com
HSBC upgrades Merck KGaA to 'Buy' on attractive valuation

HSBC has raised Merck KGaA from “Hold” to “Buy” and names the company one of its favorites in the life‑science‑tools sector due to an attractive relative valuation. Analysts highlight strong growth in the first half of the year but note that the stock did not join the recent sector rally and that a slowdown in the second half is possible from inventory drawdown and controversial M&A mark‑ups. Despite these concerns, HSBC still expects structural growth, sees offset from an accelerating electronics segment, and views the expansion of cell‑therapy capacity positively over the long term; the share price rose about 1.7%. » More on de.investing.com
Merck: €1,000 investment three years ago now about 15.5% down

Someone who bought €1,000 of Merck shares at the closing price of €166.00 three years ago would now have 6.024 shares in their portfolio. At a price of €140.25 on 28.08.2026 the investment is worth €844.88, a decline of 15.51%. All Merck shares most recently had a market value of €60.98 billion; stock splits and dividends were not taken into account in the calculation. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Merck Gruppe has already paid €2.20 in dividends. The last payout was in April.

Financials

In the last quarter, Merck Gruppe had revenue of €5.43B and net profit of €490M

(EUR)	June 2026	YoY
Revenue	5.43B	3.41%
Gross profit	3.17B	4.59%
Net profit	490M	24.85%
EBITDA	1.73B	26.89%

Fundamentals

Metric	Value
Market capitalization	€57.2B
Number of shares	434.46M
52-week high/low	€148.80 - €100.70
Dividend yield	1.67%
Dividends TTM	€2.20
Beta	0.81
P/E ratio	24.16
PEG ratio	-1.41
P/B ratio	1.90
P/S ratio	2.71

Company profile

Die MERCK Kommanditgesellschaft auf Aktien ist weltweit in den Bereichen Gesundheitswesen, Biowissenschaften und Elektronik tätig. Sie erforscht, entwickelt, produziert und vermarktet pharmazeutische und biologische verschreibungspflichtige Medikamente zur Behandlung von Neurologie und Immunologie, Onkologie, Fruchtbarkeit sowie kardiologischem Stoffwechsel und Endokrinologie. Das Unternehmen liefert auch Produkte, Werkzeuge und Dienstleistungen für Forschungslabors, die Pharma- und Biotech-Produktion sowie für Industrie- und Testlabors. Darüber hinaus bietet es Material für integrierte Schaltkreise, Flüssigkristalle, organische Leuchtdioden, Fotolacke, intelligente Antennen und Flüssigkristall-Verglasungslösungen sowie Effektpigmente für den Einsatz in Autolacken, Kosmetika, Industrie- und Kunststoffanwendungen an. Das Unternehmen unterhält strategische Allianzen mit Pfizer Inc. und eine Vereinbarung mit der Novartis AG sowie Lizenzvereinbarungen mit Debiopharm International SA und MoonLake Immunotherapeutics AG. Das Unternehmen wurde 1668 gegründet und hat seinen Hauptsitz in Darmstadt, Deutschland. Die MERCK Kommanditgesellschaft auf Aktien ist eine Tochtergesellschaft der E. Merck Kommanditgesellschaft.